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There is accumulating evidence that cancer stem cells (CSCs) play an important role in tumor progression. Novel strategies tar-
geting CSCs have been widely researched. In the present study, we explored whether such CSCs existed in human ovarian cancer 
(OVCA) cell line and whether anti-CD44 antibody had effects on such subpopulation. We isolated and identified spheroid cells 
from SKOV-3. Then we used A3D8, an anti-CD44 mAb to treat spheroid cells with so-called “stemness”. Effects of A3D8 on 
spheroid cells’ biological behaviors were examined. Our findings showed that there was a small subpopulation that had so-called 
“stemness” in SKOV-3 cell line. Against spheroid cells, A3D8 can (1) inhibit cell proliferation; (2) change cell cycle distribution 
and expression of p21, CDK2 and cyclinA; (3) enhance cisplatin (DDP)-induced apoptosis; (4) promote cell differentiation; (5) 
inhibit clone formation efficiency; (6) reduce invasive efficacy; (7) inhibit tumorigenicity. Thus, to sum up points which we have 
just showed, spheroid cells isolated from SKOV-3 can be used as an appropriate in vitro model for relevant study of human ovar-
ian CSCs. And our results reasoned that anti-CD44 therapy may become a potential promising strategy for OVCA treatment. 
cancer stem cell (CSC), targeting therapy, CD44, antibody, ovarian cancer (OVCA) 
 
Citation:  Gu C, Du Y R, Gao Y, et al. Anti-CD44 mAb remodels biological behaviors of spheroid cells with stemness from human ovarian cancer cell line 




Recently, there is accumulating evidence that cancer stem 
cells (CSCs) or cancer progenitor cells play an important 
role in cancer initiation, progression, metastasis and re-
sistance to conventional therapies (including tumor surgical 
ablation, radiotherapy and chemotherapy, alone or in com-
bination). Therefore it is necessary to explore new strategies 
targeting these tumor stem/progenitor cells to improve the 
efficacy of cancer treatment [1–7]. Currently, use of an-
ti-CD44 mAb as a potential treatment strategy targeting 
leukemia stem cells (LSCs) as well as leukemia cells has 
been extensively studied. Many research groups reported 
that anti-CD44 mAb had multiple effects on LSCs as well 
as leukemia cells, such as promoting differentiation, inhib-
iting proliferation, inducing apoptosis in vitro and decrease 
potential of tumorigenicity [8–12]. However, whether an-
ti-CD44 mAb has similar effects on CSC population in hu-
man OVCA which is the leading cause of death among gy-
necological neoplasms in the world was still unclear. Recent 
publications reported that there was a minor subpopulation 
with “stemness” in primary human ovarian tumor bulk [13] 
and ascites sample [14]. Moreover, this small subpopulation 
has been considered to be responsible for OVCA progres-
sion. But up to date, whether this subpopulation exists in 
well-established human OVCA cell line, and whether an-
ti-CD44 mAb is effective on such subpopulation, are still 
unknown and need to be explored. Therefore, in our present 
study, we managed to isolate spheroid cells from SKOV-3, 
a widely-used and a well-established human OVCA cell line, 
and evaluated their stem cell-like biological behaviors. 
Subsequently, we used A3D8, one widely-used anti-CD44 
mAb against all CD44 isoforms [15], to treat spheroid cells 
to evaluate therapeutic effects of anti-CD44 mAb on stem 
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cell-like subpopulation. 
1  Materials and methods 
1.1  Cell line and culture  
Human OVCA cell line SKOV-3 (ATCC) was cultured in 
RPMI1640 supplemented with 10% fetal bovine serum 
(FBS; Sigma, USA), penicillin, streptomycin and L-gluta- 
mine. The cell line was grown in log phase at 37°C in 5% 
CO2 atmosphere. SKOV-3 cells grew as adherent monolay-
er and then were regularly digested with 0.25% trypsin 
containing 0.02% EDTA to make single cell suspension for 
relevant assays. 
1.2  Spheroid cells isolation and culture 
Cell culture and passages were conducted following pub-
lished protocols [13,14]. In brief, adherent SKOV-3 cells 
were gently trypsinized into single cell suspension and 
seeded in T25 culture flask at a density of 4×10
3 cells/cm2 in 
serum-free DMEM/F12 culture medium supplemented with 
5 µg/mL insulin (Sigma), 1 ng/mL hydrocortisone (Sigma), 
20 ng/mL human recombinant epidermal growth factor 
(hrEGF; Invitrogen, USA), 10 ng/mL basic fibroblast 
growth factor (bFGF; Invitrogen), 5 ng/mL stem cell factor 
(SCF; Invitrogen), 2% B27 and 0.4% bovine serum albumin 
(BSA; Sigma). After 5–7 d incubation, primary spheroids 
were observed. The primary spheroid cells were trypsinized 
and further cultured. The secondary spheroids were isolated 
for further expansion. 
1.3  Cell proliferation rate assay 
Freshly trypsinized single spheroid cells were seeded in 
96-well culture plates in 100 μL serum-free medium de-
scribed above at a density of 1×104 cells/well. The cells 
were treated with different concentration of mAb A3D8 
(Sigma) (1, 10, 50 µg/mL) for 48 h. Three hours before the 
end of incubation, MTT was added into each well (final 
concentration of MTT is 5 mg/mL). At the end of incuba-
tion, medium in each well was removed and deposit was 
dissolved in 150 µL DMSO. The relative formazane con-
centration was measured by determination of absorbance at 
573 nm (Well-plate Reader, Thermo). Mouse IgG1 (mIgG1) 
was used as isotype control. 
1.4  Immunocytochemistry assay 
Freshly trypsinized spheroid cells were seeded in 24-well 
plate containing glass coverslip in serum-free medium men-
tioned above (1×105 cells/mL per well), followed by treat-
ing with 10% serum, mIgG1 or A3D8 (10 μg/mL) for 7 d 
respectively. Morphology of cells was observed under mi-
croscope (Olympus, Japan) every day. The expression of 
CK-7 and CA125 was assessed by regular immunocyto-
chemistry assay respectively. The antibodies included 
mouse anti-human CA125 mAb (Santa Cruz), mouse anti- 
human CK-7 mAb (Santa Cruz) and horseradish peroxi-
dase-labeled goat anti-mouse IgG secondary antibody (San-
ta Cruz). Diaminobezidin (DAB) Kit (Santa Cruz) was used 
as color indicator system. Quantification of cells stained 
with each antibody (brown color) was estimated as a per-
centage of brown cells in total cells in each microscopic 
field. Cells were counted in at least 5 microscopic fields per 
specimen. 
1.5  Analysis of ALDH enzymatic activity  
Analysis of aldehyde dehydrogenase (ALDH) enzymatic 
activity was performed using Aldefluor system (Miltenyi) 
following manufacturer’s instructions. Briefly, cells were 
trypsinized and resuspended in phosphate buffer solution 
(PBS) supplemented with 2% FBS at a concentration of 
1×106 cells/mL. One milliliter of above cell resuspension 
was mixed with 2 µL Aldefluor substrate, then half of re-
suspended cells were immediately placed into a fresh vial 
with 5 µL diethylaminobenzaldehyde (DEAB), a specific 
inhibitor of ALDH for negative control. Both tubes were 
incubated at 37°C for 30 min. After incubation, cells were 
resuspended in the above fresh buffer and analyzed. Analy-
sis was performed by using a flow cytometer (FACSCalibur, 
BD) equipped with a 488 nm argon ion laser for excitation 
and a 525 nm band pass filter. ALDH+ cells are identified as 
cells with low side scatter and high green fluorescence.  
1.6  Apoptosis detection 
The percentage of apoptotic cells was detected by flow cy-
tometry using PI/Annexin V-FITC Kit (Keygen, China) 
according to manufacturer’s recommendations. Briefly, 
cells were harvested and washed twice with PBS containing 
2% FBS, followed by staining with annexin V-fluorescein 
isothiocyanate (FITC) and propidium iodide (PI). Flow cy-
tometry analysis was last performed. The compensation was 
modified using cells labeled with annexin V-FITC or with 
PI alone. Ten thousand of events were acquired for each 
sample. CellQuest Pro software (BD, USA) was used to 
acquire and analyze data. 
1.7  Cell cycle analysis 
Cells were fixed with 70% ethanol overnight at –20°C and 
incubated with RNase (50 µg/mL) and PI (2.5 µg/mL) for 
30 min at 4°C followed by flow cytometry. CellQuest Pro 
software was used to acquire data and results obtained were 
analyzed using ModFit LT Version 3.2 software to deter-
mine percentage of cells in G0/G1, S, G2/M phases of cell 
cycle [16].  
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1.8  Cell extracts and Western blot analysis  
Proteins were extracted from spheroid cells and adherent 
SKOV-3 cells using Protein Extract Kit (Pierce). Total pro-
tein concentrations in each fraction were determined with 
BCA Protein Assay Kit (Pierce). Identical amounts of pro-
tein were separated on 12% SDS/PAGE (50 μg/lane) and 
electroblotted onto polyvinylidene fluoride membrane (Pall). 
The transfer was monitored by a prestained protein molecu-
lar weight marker (Invitrogen). After transfer, membranes 
were blocked with 5% skim milk in 50 mmol/L Tris-HCl 
(pH 7.4), 150 mmol/L NaCl, and 0.05% Tween-20 (TBS) 
for 1 h at room temperature. Immunoblotting was per-
formed by incubation with a specific primary antibody 
overnight at 4°C. Primary antibodies included mouse mAbs 
against human Nanog, Oct-4, ABCG2, p21, CDK2, cyclinA 
and bcl-2 (Santa Cruz). After washing three times for 30 
min in TBS, membranes were secondly hybridized to pe-
roxidase-labeled goat anti mouse antibody for detection 
with ECL chemoluminescence system (Santa Cruz).  
1.9  Analysis of mitochondrial transmembrane poten-
tial (ΔψM) 
Mitochondrial transmembrane potential was measured by 
flow cytometry using Rhodamine 123 (Rh123) Detection 
Kit (Keygen). Briefly, harvested cells were washed twice 
with PBS and incubated with 1 μg/mL Rh123 at 37°C for 
30 min. Cells were then washed twice with PBS, and Rh123 
intensity was determined by flow cytometry. Cells with 
reduced fluorescence (less Rh123) were counted as having 
lost some of their mitochondrial transmembrane potential.  
1.10  Clone formation assay 
Freshly trypsinized spheroid cells were seeded in 96-well 
plate (1×104 cells/mL, 100 μL/well), and then treated with 
mIgG1 or A3D8 (10 μg/mL) for 48 h respectively. Each 
kind of above pretreated cells were trypsinized and re-
counted, and then soft-agar colony formation assay was 
performed according to what we described previously [17]. 
Briefly, cells were seeded in triplicate in 6-well plate with 
1×104 cells/well and incubated in soft agar for 14 d at 37°C 
using a two layer agar system and clones were counted. The 
clone formation efficiency (CFE) was ratio of clone number 
to planted cell number.  
1.11  In vitro matrigel invasion assay 
Matrigel invasion assay was performed in 24-well invasion 
chamber system (Costar) of 6.5 mm diameter, with 8 µm 
pore filters. Briefly, filter membrane was coated overnight 
at 4°C with fibronectin (FN, 20 μg/mL, BD) and then coat-
ed with matrigel (200 μg/mL, 50 μL/well, BD) at 37°C for 1 
h. A total of 1×105 spheroid cells were pretreated with 
mIgG1 or A3D8 (10 µg/mL) for 48 h respectively, and then 
were trypsinized and recounted. A total of 1×105 cells pre-
treated above in 0.1 mL assay medium (DMEM/F12 with 
0.25% BSA) were added to upper compartment, and 0.6 mL 
DMEM/F12 medium supplemented with growth factors in 
the presence of 5% FBS was added to lower compartment. 
After 48-h incubation, remaining tumor cells on upper sur-
face of filters were removed by wiping with cotton swabs, 
and invading cells on lower surface were stained using reg-
ular HE staining. The cells number on lower surface of fil-
ters was counted under a microscope (Nikon, Japan). Data 
were obtained from three individual experiments in tripli-
cate.  
1.12  Evaluation of spheroid cells’ tumorigenicity in 
NOD/SCID mice 
Freshly trypsinized spheroid cells and adherent SKOV-3 
cells were resuspended in serum-free culture described 
above. Cells were diluted to appropriate injection doses, and 
injected subcutaneously in NOD/SCID mice on the side of 
each flank. Briefly 12 NOD/SCID mice were randomly 
grouped into 6 groups, 2 mice per group. The spheroid cells 
(1×102, 1×103 or 1×104), and SKOV-3 adherent cells (1×104, 
1×105 or 1×106) were respectively inoculated into NOD/ 
SCID mice as described above. Mice in each group were 
monitored. When tumors reached a maximum diameter of 
15 mm or up to 4 months after cell inoculation without ob-
vious tumor occurrence, the mice would be sacrificed and 
tumors were retrieved at the end of experiment for patho-
logic analysis.  
1.13  Animal test for effect of A3D8 on tumorigenicity  
Freshly trypsinized spheroid cells were seeded in 6-well 
plates in 1 mL of serum-free medium described above at a 
density of 1×105 cells/mL. After 24-h regular incubation, 
cells were then treated with A3D8 at 10 μg/mL or mIgG1 at 
the same concentration as control. Twelve six-week-old 
NOD/SCID mice were randomly grouped into four groups, 
three mice per group. Each group of mice were injected 
subcutaneously on the flank with A3D8-pretreated spheroid 
cells (1×104 or 1×105) or mIgG1-pretreated spheroid cells 
(1×104 or 1×105) suspended in PBS. The animals were ob-
served daily. When tumors’ diameter of control group mice 
reached 15 mm, mice were sacrificed and tumors were re-
trieved at the end of experiment for pathologic analysis. All 
experiments involving use of animals were performed in 
accordance with Tianjin Medical University institutional 
animal welfare guidelines. 
1.14  Statistical methods  
Microsoft Office Excel 2007 and statistical software SPSS 
16.0 were used in data processing and in analyzing signifi-
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cance between groups with paired t test. P<0.05 was con-
sidered significant. The results were presented as mean ± 
SD of three independent experiments.    
2  Results 
2.1  The spheroid cells from SKOV-3 have so-called 
stemness  
To identify whether spheroid cells isolated from SKOV-3 
had stemness, a batch of tests were performed. The data 
showed that spheroid cells exhibited the ability to unlimit-
edly divide in an anchorage-independent spheroid manner 
in serum-free medium supplemented with growth factors for 
at least 6 months without obvious phenotype change. This 
growth pattern is regarded as a growth manner of cancer 
stem/  progenitor cells under stem cell-selective conditions 
[13,14]. After passages, spheroid cells persisted as larger, 
symmetric prototypical spheroids. Typical spheroids con-
tained 50–100 viable cells (Figure 1(a)). Considering cell 
cycle event characteristics of stem/progenitor cells, we also 
detected cell-cycle events of spheroid cells (SKOV-3 cells as 
control) by regular PI staining by flow cytometry. The data 
showed that about 85.23±2.36% spheroids and 55.03± 
4.07% SKOV-3 cells presented in G0/G1 phase (Figure 
1(b)). This result is consistent with the studies by Matsui et 
al. [18] and Takubo et al. [19] on cell cycle event of stem/ 
progenitor cells. As to the induction of spheroid cells’ dif-
ferentiation, according to Zhang et al. [13], spheroids were 
cultured under differentiating conditions (e.g., addition of 
10% FBS after growth factors’ withdrawal) for 7 d, floating 
spheroids could adhere to culture plate, acquire an epithelial 
morphology and express epithelial markers CK-7 and ovar-
ian CA125. And percentage of CK-7 positive and CA125 
positive cells in total cell event were 50±6% and 45±5% 
respectively (Figure 1(c)). In addition, genes expression of 
Oct-4 and Nanog are regarded as marker of embryonic stem 
cells and stem cell expansion [14,20], so expression of 
Nanog and Oct-4 in spheroid cells were examined by West-
ern blot assay. The result showed that, compared with ad-
herent SKOV-3 cells, spheroid cells showed significantly 
stronger signal. Moreover, expression of ABCG2, encoding 
a membrane efflux transporter and expressed in hematopoi-
etic stem cells and associated with chemotherapy resistance 
[20], was also assessed by the same method. Results showed 
that spheroid cells expressed stem cell-relevant marker 
(Figure 1(d)), providing further evidence for their undifferen-




Figure 1  (Color online) Under stem cell selective-condition, spheroid cells from SKOV-3 displayed stem cell characteristics. (a) Morphology result of 
adherent SKOV-3 cells cultured in standard 10% FCS RPMI 1640 medium and typical spheroids in serum-free selective medium supplemented with growth 
factors after passages. (b) Cell cycle event of spheroids and SKOV-3 cells by regular PI staining using flow cytometry. (c) Morphology, expression of CK-7 
and CA125 in spheroid cells by immunocytochemistry versus differentiated cells cultured under differentiating conditions. (d) Expression of Nanog, Oct-4, 
and ABCG2 in spheroid cells versus adherent SKOV-3 cells by Western blot analysis. (e) Flow cytometry analysis of ALDH+ cells in spheroid cells. (f) 
Xenograft tumor formed after injection of spheroid cells. Injection of 1×104 spheroid cells per mouse subcutaneously on the back of NOD/SCID mice gener-
ated tumors with 2/2 efficiency. HE staining sections of primary tumor reproduced by 1×104 spheroid cells. 
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that ALDH, an enzyme involved in stem cell self-protection, 
is regarded as another important property of stem cells [21]. 
Therefore we further detected ALDH activity of spheroid 
cells by flow cytometry. The data exhibited that about 75% 
of spheroid cells was ALDH+ cells and had a high level of 
ALDH activity (Figure 1(e)). The last but not least of all, 
tumorigenicity of spheroid cells in NOD/SCID mice was 
also assessed. Results showed that as few as 1×104 spheroid 
cells injected into NOD/SCID had the ability to reproduce 
tumor exhibiting similar phenotype to that reproduced by 
1×106 adherent SKOV-3 cells. This result indicated that, 
compared with SKOV-3 cells, exponentially smaller num-
ber of spheroid cells could reproduce tumor (Figure 1(f) and 
Table 1).  
2.2  A3D8 inhibited spheroid cell proliferation rate  
To evaluate whether A3D8 has effects on proliferation    
of spheroid cells, MTT assay was performed. The data 
showed that A3D8 significantly decreased proliferation rate 
of spheroid cells in a dose-dependent manner (P<0.05) 
(Figure 2). 
2.3  A3D8 decreased fraction of spheroid cells in G0/G1 
phase and regulated expression of p21, CDK2 and cy-
clinA 
To determine whether A3D8 can affect cell cycle distribu-
tion of spheroid cells, we treated spheroid cells with A3D8 
at 10 μg/mL for 48 h, and cell cycle was then analyzed. Plot 
data showed that G0/G1 percentages of mIgG1 or 
A3D8-treated spheroid cells were 86.02±2.95% and 
59.70±3.25%, respectively (P<0.05); while those in S phase 
were 7.82±0.90% and 28.97±3.65%, respectively (P<0.05) 
(Figure 3(a–c)). Western blot showed that A3D8 upregulat-
ed expression of p21 while downregulated CDK2 and cy-
clinA levels (P<0.05) (Figure 3(d) and (e)). 
2.4  A3D8 enhanced DDP-induced apoptosis of sphe-
roid cells 
In the present study, we treated spheroid cells with 10 
μg/mL mIgG1, 10 μg/mL A3D8 at 2.5 μg/mL DDP, or 10  
Table 1  Tumorigenicity of spheroid cells and SKOV-3 cells in NOD/ 
SCID mice  









a) Two mice per group. 
μg/mL A3D8 plus 2.5 μg/mL DDP for 24 h respectively, 
and then apoptosis rate was analyzed. Data showed A3D8 
could significantly enhance DDP-induced apoptosis of 
spheroid cells (the percentage of apoptotic cells were 
5.800.43%, 9.931.24%, 10.520.51% and 15.031.23% 
for mIgG1, A3D8, DDP and A3D8 plus DDP treatment, 
respectively) (Figure 4(a)). In further mechanism study, we 
detected two key indicators in mitochondrial apoptotic 
pathway (including bcl-2 expression and change of mito-
chondrial ∆ψM). The results showed that A3D8 could 
downregulate bcl-2 expression and change mitochondrial 
∆ψM (Figure 4(b) and (c)). It indicated that A3D8 enhanced 
DDP-induced apoptosis of spheroid cells, which was rela-
tive with mitochondrial apoptotic pathway, to some extent. 
2.5  A3D8 promoted differentiation of spheroid cells  
To investigate whether A3D8 has effects on differentiation 
of spheroid cells, we treated freshly trypsinized spheroid 
cells with mIgG1 or A3D8 at 10 μg/mL for 7 d respectively. 
We discovered that, compared with those treated with 
mIgG1, spheroid cells treated with A3D8 adhered to the 
plate, acquired an epithelial morphology (Figure 5(a)). We 
also evaluated expression of epithelial OVCA markers 
(such as CK-7 and CA125) by immunocytochemistry assay. 
The data demonstrated that A3D8 significantly promoted 
expression of CK-7 and CA125, and increased percentage 
of CK-7 positive cells to 39±5%, and percentage of CA125 
positive cells to 46±6% (Figure 5(b)). The data indicated 
that A3D8 could promote differentiation of spheroid cells. 
 
 
Figure 2  A3D8 inhibited proliferation rate of spheroid cells from 
SKOV-3. Spheroid cells (1×105 cells/mL) were treated with different con-
centration of mIgG1 or A3D8 at 1, 10 and 50 μg/mL respectively for 48 h. 
Cell proliferation rate was determined using MTT assay. A3D8 decreased 
proliferation rate of spheroid cells in a dose-dependent manner. Data are 
means from three measurements; error bars show standard deviations,  
indicates P<0.05. 
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Figure 3  (Color online) A3D8 changed cell cycle distribution of spheroid cells from SKOV-3. Spheroid cells were pretreated with mIgG1 or A3D8 at 10 
μg/mL for 48 h respectively, and cell cycle analysis by PI staining using flow cytometry was performed. Plot data showed that A3D8 decreased percentage 
of G0/G1 while increased percentage of S phase. Histogram data of three independent tests were shown. Cells were pretreated with mIgG1 (a) or A3D8 (b). 
(c) Bar diagram showed the result of three separate experiments. (d) Western blot results showed that A3D8 could upregulate expression of p21 while 
downregulate that of CDK2 and cyclinA. (e) Bar diagram showed the result of three separate experiments. Data are means from three measurements; error 
bars show standard deviations,  indicates P<0.05. 
 
Figure 4  (Color online) A3D8 enhanced DDP-induced apoptosis of spheroid cells from SKOV-3. (a) Spheroid cells were treated with 10 μg/mL mIgG1 or 
10 μg/mL A3D8 or 2.5 μg/mL DDP or 10 μg/mL A3D8 plus 2.5 μg/mL DDP for 24 h respectively, and flow cytometry analysis results of spheroid cells 
were shown. (b) Western blot results showed that A3D8 could downregulate bcl-2 expression. Data are means from three measurements; error bars show standard 
deviations,  indicates P<0.05. (c) Flow cytometry analysis of Rh123 staining showed that A3D8 could change mitochondrial ∆ψM of spheroid cells.  
2.6  A3D8 inhibited CFE of spheroid cells 
To determine whether A3D8 has effects on clone-formation 
of spheroid cells, we pretreated freshly trypsinized spheroid 
cells with A3D8 at 10 μg/mL for 48 h, and then CFE was 
assessed. The data demonstrated that CFE of spheroid cells 
pretreated with A3D8 was obviously lower than that pre-
treated with mIgG1 (P<0.05) (Figure 6). 
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Figure 5  (Color online) A3D8 promoted differentiation of spheroid cells. The spheroid cells were pretreated with mIgG1 or A3D8 at 10 μg/mL for 48 h 
respectively. The morphology of cells was observed under microscope every day. Expression of CK-7 and CA125 was evaluated by immunocytochemistry 
assay. (a) Typical morphology change of one spheroid treated with A3D8 for 7 d. (b) Expression of CK-7 and CA125 in spheroid cells treated with mIgG1 
versus that treated with A3D8.  
 
Figure 6  (Color online) A3D8 inhibited CFE of spheroid cells. (a) The 
CFE of spheroid cells pretreated with A3D8 was much lower than that of 
spheroid cells pretreated with the same dose of mIgG1. After 14-d culture, 
most clones had reached >50 cells. (b) The clone that contained more than 
50 cells was counted under a microscope. The data showed that A3D8 
inhibited significantly CFE of spheroid cells. Data are means from three 
measurements; error bars show standard deviations,  indicates P<0.05. 
2.7  A3D8 reduced invasive efficacy of spheroid cells  
To investigate whether A3D8 has effects on invasion of 
spheroid cells, we pretreated freshly trypsinized spheroid 
cells with A3D8 at 10 μg/mL for 48 h, and then transferred 
them into transwell-plate pretreated with fibronectin and 
matrigel. After incubation for 48 h, invaded cells were 
evaluated. The data showed that, compared with control, 
A3D8 significantly reduced invasive efficacy of spheroid 
cells (P<0.05) (Figure 7). 
2.8  A3D8 decreased tumorigenicity of spheroid cells in 
NOD/SCID mice 
In order to evaluate effect of A3D8 on tumorigenesis in vivo 
we injected A3D8-pretreated spheroid cells (1×104 or 1×105) 
into NOD/SCID mice, with mIgG1-pretreated spheroid cells 
as control. Sixteen weeks later, all mice were sacrificed and 
tumors were retrieved for pathologic analysis. The results 
showed that, in two control groups, 2 of 3 mice (1×104 cells), 
and 3 of 3 mice (1×105 cells) respectively reproduced tumor; 
however, in two tested groups, none of 3 mice (1×104 cells) 
and 1 of 3 mice (1×105 cells) respectively reproduced   
tumor. The results indicated that A3D8 significantly de-




Figure 7  (Color online) A3D8 inhibited invasive efficacy of spheroid 
cells from SKOV-3. (a) The spheroid cells were pretreated with mIgG1 or 
A3D8 at 10 μg/mL for 48 h respectively, and then transferred them to 
transwell chamber pretreated with fibronectin and matrigel. After 48-h 
incubation, membrane of each well was stained with HE. (b) Cells number 
on lower surface of filter was counted under a microscope. The data 
showed that A3D8 significantly inhibited invasive efficacy of spheroid 
cells. Data are means from three measurements; error bars show standard 
deviations,  indicates P<0.05. 
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Table 2  A3D8 inhibited tumorigenicity of spheroid cells in NOD/SCID 
mice 
Groups Cell dose Tumor formation a) 
mIgG1-pretreated spheroid cells 
1×104 2/3 
1×105 3/3 
A3D8-pretreated spheroid cells 
1×104 0/3 
1×105 1/3 
a) Three mice per group. 
3  Discussion  
Mounting evidence demonstrated that CSCs play an im-
portant role in tumor progression. Novel strategies targeting 
CSCs have been widely explored. The present study 
demonstrated that there existed a small population with 
so-called “stemness” property in well-established human 
OVCA cell line (SKOV-3) and anti-CD44 mAb could re-
model some biological behavior of such subpopulation. 
Recently, it is assumed that many established malignant 
cell lines contain a rare subpopulation of stem cells that can 
be maintained indefinitely in culture, and play crucial role 
in malignancy [22–26]. Moreover, some studies reported 
that minor subpopulation is enriched in side population (SP), 
and there is a positive correlation between SP cells and stem 
cells [24,27]. Therefore, first of all we detected SP cells in 
four well-establish human OVCA cell lines (including 
SKOV-3, OVCAR-3, Caov-3, and HO-8910). The data il-
lustrated percentage of SP cells in above four cell lines is 
about 0.6±0.1%, 0.1±0.1%, 0.3±0.2%, 0.2±0.2% respec-
tively. Among four cell lines, percentage of SP cells in 
SKOV-3 is the highest (Figure 8). Therefore we next man-
aged to isolate stem/progenitor cells from SKOV-3. 
To date, in general, there are several methods to isolate 
tumor cells with stem/progenitor property, including (1) 
isolating SP by flow cytometry as CSCs [24,27]; (2) isolat-
ing so-called CSCs by specific surface markers [28,29]; (3) 
isolating spheroid cells in serum-free culture condition 
[13,14,30,31]. So in the present study, we exploited method 
described by Bapat et al. [14] to isolate spheroid cells from 
SKOV-3 cells in serum-free culture condition. As to the 
identification of CSCs, putative criteria includes following 
aspects: firstly, like normal adult stem cells, CSCs exhibit 
the ability to unlimitedly divide as well as give rise to dif-
ferentiated tissue cells in vitro [13,14,19,32]; secondly, 
CSCs express putative stem cell-relevant markers (such as 
Nanog, Oct4, ABCG2, etc.) [14,20]; thirdly, quiescence of 
CSCs, namely most CSCs are in G0/G1 phase in cell cycle 
[33]; fourthly, a small quantity of so-called CSCs can re-
produce tumor in NOD/SCID mice [13,14,19,32]. Accord-
ingly, we identified isolated cells from several aspects de-
scribed above. Our data showed that spheroid cells grew 
exponentially in vitro in serum-free medium in an anchor- 
independent manner for more than 6 months without obvi-
ous phenotype change; cell cycle analysis showed that about 
 
Figure 8  (Color online) SKOV-3 cell line contained a small quantity of 
SP (side population). Cells from SKOV-3 were stained with Hoechst 
33342 and analyzed by flow cytometry. (a) The SP cells were outlined and 
shown as a percentage of total cell population. (b) This cell population 
disappeared in the presence of verapamil. 
85.23±2.36% cells were in G0/G1 phase; after adding 10% 
serum to conditioned medium, spheroid cells expressed pu-
tative epithelial OVCA differentiation antigen, such as 
CK-7 and CA125; these spheroid cells expressed putative 
stem/progenitor cell-relevant marker proteins, such as Oct-4, 
Nanog, and ABCG2; and these spheroid cells also had high 
ALDH activity. Moreover, only 1×104 spheroid cells in-
jected into NOD/SCID mice had the ability to reproduce 
tumor with similar phenotype to that reproduced by 1×106 
adherent SKOV-3 cells. Our data implied existence of a 
small subpopulation that had so-called “stemness” in 
SKOV-3 cell line and could be propagated. 
Thereafter, we evaluated influence of anti-CD44 mAb 
(A3D8) on behaviors of the above spheroid cells with 
stem/progenitor property. First, we detected expression of 
CD44 molecule on the surface of spheroid cells. The plot 
data showed that about 88% spheroid cells expressed CD44 
at high level (Figure 9). That is not only similar to the re-
sults reported by Zhang et al. [13] but also is the basis of 
our following experiments.  
CD44 comprises a family of membrane adhesion mole-
cules encoded by a single gene and diversified by alterna-
tive splicing and extensive posttranslational modifications, 
known as CD44 variant isoforms (generally including 
CD44s and CD44v). The expression pattern of CD44s and 




Figure 9  (Color online) Expression of CD44 in spheroid cells: (a) isotype 
control; (b) test group. Three independent experiments were done, and 
percentage of CD44 positive cells was 86.34±1.58%. 
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upon tumor type and origin [34]. Cho et al. [35] demon-
strated that overexpression of CD44s was significantly as-
sociated with high tumor grade of ovarian neoplasms.  
A3D8, purified from A3D8 hybridoma, is a kind of 
mouse monoclonal anti-CD44 antibodies and may recognize 
all CD44 isoforms [15]. Since CD44 is strongly expressed 
on surface of many human cancer cells and CSCs, an-
ti-CD44 antibodies are widely-used in anti-cancer studies 
[8–11]. Recently, it is reported that targeting CD44 with 
activating mAbs has led to eradication of human LSCs [12]. 
This indicates that such CSC-targeting therapy may be a 
promising approach for cancer treatment. However, there 
are few reports about antibody-based CSC-targeting therapy 
for solid tumor, such as OVCA. Accordingly, we used 
A3D8 to treat spheroid cells from SKOV-3, one of OVCA 
cell lines, and conducted a batch of testing to evaluate in-
fluence of A3D8 on behaviors of spheroid cells with 
“stemness”. Our data showed that A3D8 could significantly 
inhibit proliferation of spheroid cells and promote them to 
differentiate. These results are similar to results reported by 
Gadhoum et al. [11].  
Apoptosis detection test in our present study showed that 
apoptosis of spheroid cells was significantly enhanced after 
DDP treatment combined with A3D8. The analysis of mi-
tochondrial transmembrane potential and bcl-2 expression 
supported the data from apoptosis assay. We proposed that 
A3D8 may downregulate bcl-2 expression and then de-
crease stability of mitochondrial membrane and cause 
eventual cell death. The results supported that A3D8 had 
advantage on increasing chemosensitivity of spheroid cells 
to conventional chemotherapy drugs (such as DDP).  
Cell cycle analysis in our current study showed that 
A3D8 could reduce fraction in G0/G1 phase, companied by 
S-phase arrest, of spheroid cells. It has been reported that 
high portion of G1 in tumor cells was closely related to 
chemo-resistant and anti-apoptotic behaviors [33,36]. Thus 
we supposed that cell cycle distribution change of spheroid 
cells described above may be a presumable reason for de-
creased proliferation by A3D8 and also for enhanced apop-
tosis of spheroid cells induced by A3D8 plus DDP com-
pared to DDP alone. The data also showed that A3D8 could 
regulate expression of p21, CDK2 and cyclinA, which are 
important protein regulators in cell cycle. These results indi-
cated that there might be a correlation existing between de-
crease in the fraction of spheroid cells in G0/G1 phase with S 
arrest and changes of p21, CDK2 or cyclinA expression. 
It is notable that OVCA may spread by implantation of 
tumor cells onto mesothelial lining of peritoneal cavity [37]. 
One important mechanism is interaction between hyaluronic 
acid and CD44 receptor [38]. A conventional curative 
treatment is however difficult to achieve. Therefore, pre-
venting tumor-cells binding to mesothelium is crucial for 
patients’ outcome. It is possible that strategies to interfere 
CD44s function may decrease chance of intra-abdominal 
spread of this highly lethal neoplasm [37]. Thus, in the cur-
rent study, we employed in vitro model of invasion assay 
using matrigel-coated membrane to measure the influence 
of A3D8 on invasion ability of spheroid cells. Our data 
demonstrated that A3D8-pretreated spheroid cells had very 
low invasion potential. The result indicated that A3D8 
might interfere with spreading process of OVCA cells. Ad-
ditionally, our data showed that A3D8 strongly decreased 
CFE of spheroid cells. This result indicated that A3D8 
might also decrease possibility of tumor-reproduction in a 
relocated site. Results also showed that A3D8 could de-
crease tumorigenicity of spheroid cells in NOD/SCID mice. 
All these data ensure potential of A3D8 to be a novel and 
promising tool in target-strategy against OVCA.  
In conclusion, for the first time, we isolated and identi-
fied spheroid cells with so-called “stemness” property from 
human OVCA cell line SKOV-3; and our present study re-
vealed that anti-CD44 therapy may become a novel and 
promising target-strategy for OVCA treatment.  
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